This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.bbc.co.uk/news/health-30577776

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Ebola vaccine 'promising in African populations' Ebola vaccine 'promising in African populations'
(1 day later)
The first-ever trial of an Ebola vaccine in Africa shows promising initial results, according to a report in the Lancet medical journal. The first-ever trial of an Ebola vaccine in Africa showed promising initial results, reports the Lancet medical journal.
Scientists say it is a crucial step as other vaccines have shown lower levels of protection in African populations. The vaccine, given to Ugandan and American volunteers, appeared to generate the desired immune response - although not enough to make it a good candidate for wider use.
Tests involving Ugandan and American volunteers reveal the vaccine is so far safe and generates an immune response in both populations. Scientists say although it will not beat Ebola, it is a crucial step.
It provides reassurance for other trials currently underway, they say. This trial has stopped but other vaccines are in development.
The Ebola virus has killed more than 6,900 people in the worst-affected countries of Sierra Leone, Liberia and Guinea. The Ebola virus has killed more than 7,000 people in the worst-affected countries of Sierra Leone, Liberia and Guinea.
No proven vaccine exists to prevent people from getting the disease, though several trials are underway.No proven vaccine exists to prevent people from getting the disease, though several trials are underway.
The aim of a successful vaccine is to train the immune systems of healthy people to produce antibodies - proteins capable of fighting off any future infections.The aim of a successful vaccine is to train the immune systems of healthy people to produce antibodies - proteins capable of fighting off any future infections.
Viral protection The Lancet study
Researchers from the National Institutes of Health tested this experimental vaccine on healthy adults in Uganda, having first trialled it in the United States. In 2009, researchers from the National Institutes of Health (NIH) tested their experimental vaccine on healthy adults in Uganda, having first trialled it in the US.
Dr Julie Ledgerwood, the lead researcher, said: "This is the first study to show comparable safety and immune response of an experimental Ebola vaccine in an African population. Dr Julie Ledgerwood, the lead researcher of the trial that has been written up and published in The Lancet, said: "This is the first study to show comparable safety and immune response of an experimental Ebola vaccine in an African population.
"This is particularly encouraging because those at greatest risk of Ebola live primarily in Africa and diminished vaccine protection in African populations has been seen for other diseases.""This is particularly encouraging because those at greatest risk of Ebola live primarily in Africa and diminished vaccine protection in African populations has been seen for other diseases."
According to the study some 57% of people in Uganda who received the Ebola vaccine alone developed antibodies against Ebola in their blood.According to the study some 57% of people in Uganda who received the Ebola vaccine alone developed antibodies against Ebola in their blood.
Dr Sridhar of the University of Oxford, commenting on the research, said the data provided reassurance about separate Ebola virus vaccines trials currently underway in Mali, the US and the UK. Dr Sridhar of the University of Oxford, commenting on the research, said the data provided insights into Ebola vaccine development.
But further tests would be needed to see if the antibodies are strong enough and long-lasting enough to provide adequate protection against the disease. Vaccines currently being tested against Ebola are made in a different way to the NIH one.